Dompé is a privately-owned global bio-pharmaceutical company with 130 years of experience.
Prescription drugs and OTC products, dietary supplements, medical devices and cosmetics
Treatment of rare diseases and conditions with high unmet need
Diabetes, Opthalmology, and conditions with high unmet need
Europe, United States, China
More than 800 employees globally, including contractors and sales agents
Packages manufactured in 2019
Small molecule and biotech production capabilities
EMA (European Medicines Agency), Europe
FDA (Food and Drug Administration), United States
Dompé developed the application of rhNGF (recombinant human Nerve Growth Factor) approved by the FDA and EMA.
Marketing authorization granted by the EMA in addition to fast track and priority review designations by FDA
Chinese National Medical Products Administration (NMPA) inclusion among the 40 clinically needed drugs overseas
Expected Chinese NMPA marketing authorization
Dompé farmaceutici was established in 1940, growing from pharmaceutical roots in the Nineteenth Century
Gian Antonio Dompé devotes himself to studying chemical-pharmaceutical sciences and becomes a respected expert.
Onorato Dompé, Gian Antonio’s son, establishes the Dompé-Adami laboratory.
Onorato Dompé establishes the first pharmaceutical production plant in Milan.
Franco Dompé, founds Dompé farmaceutici.